ANCA-associated Vasculitis
Conditions
Brief summary
Activation of neutrophils by ANCA (Anti-Neutrophil Cytoplasm Antibodies) and subsequent microvascular endothelial cell damage is the main feature of ANCA-associated vasculitis (AAV), a severe autoimmune disease that often targets the kidney. There is no specific treatment for AAV to date and 25% of patients with renal damage evolve towards end-stage renal disease, requiring dialysis and kidney transplantation. In addition, there is no reliable biological marker of the disease activity available, which makes the diagnostic, follow-up and treatment of patients difficult. Therefore, the identification of new therapeutic targets and non-invasive biomarkers constitutes a major clinical challenge to improve AAV patients care and to ameliorate their renal outcome.
Interventions
OTHERNon interventional study
This is a non interventional study because all levies are performed during visit planned for the care of patients.
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Nantes University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
for patients: * Adult patients aged over 18 years * Patients with Granulomatosis with polyangiitis or microscopic polyangiitis meeting the criteria of Chapel Hill. * corticosteroid treatment \<20 mg / day. * Informed consent: oral for participation in research and writing for biological collection. Inclusion Criteria for controls patients: \- healthy-topics matched for age, recruited from the Etablissement français du sang or in the Department of Internal Medicine of Nantes University Hospital Non Inclusion Criteria: * ANCA-associated vasculitis with Eosinophilic granulomatosis with polyangiitis (AAV-EGPA). * Infectious or progressive tumor pathology. * Pregnancy, lactation * Treatment with cyclophosphamide in the 6 months prior to inclusion. * Terminal chronic renal failure, presence of organ allograft. * Thrust Patients receiving corticosteroids\> 20 mg / d in the previous 4 weeks. * Inability to give informed about information (subject in emergencies, understanding of the subject of difficulty, ...) * Minor subject, under judicial protection, guardianship
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression profile of miRNAs in patients with AAV in circulating neutrophils, plasma and urine. | 6 month after maintenance treatment |
Countries
France
Outcome results
None listed